Metabolic fate of the thrombolytic agent benzarone in man: comparison with the rat and dog.
S G Wood, B A John, L F Chasseaud, R Bonn, H Grote, K Sandrock, A Darragh, R F Lambe
Index: Xenobiotica 17(7) , 881-96, (1987)
Full Text: HTML
Abstract
1. The metabolic fate of 14C-benzarone in the rat and dog has been compared to that in human subjects. An oral dose was well-absorbed in all three species. However, the 14C excretion patterns differed: humans (100 mg) excreted means of 73 and 19% dose in the urine and faeces respectively, whereas the rat (2 mg/kg) and dog (0.5 mg/kg) excreted greater than 80% in the faeces, mostly during the first 48 h. 2. Much of the faecal 14C was attributable to 14C excreted in the bile which amounted to 59% in the 7 h bile collected from an intravenously dosed dog, and a mean of 72% in the 24 h bile of orally dosed rats. Enterohepatic circulation of 14C was demonstrated in rats. 3. Total 14C in human plasma reached peak concentrations between 1-2 h and declined relatively rapidly, to about 10% of this value within 24 h. Unchanged benzarone was not detected in plasma (less than 25 ng/ml), even after a 400 mg dose, but conjugated benzarone was--accounting for about 10% of the peak concentration of 14C. In the dog, by contrast, conjugated benzarone accounted for about 50% of the peak concentration of 14C of 0.96 microgram equiv./ml at 1 h. The extent of binding of benzarone to human plasma proteins (greater than 99%; in vitro was slightly greater than that (greater than 96%) of total 14C (ex vivo, representing metabolites). 4. Examination of metabolite profiles by h.p.l.c. suggested that in the rat and dog, at least 70% absorbed dose was eliminated by direct conjugation, whereas in humans at least 70% was hydroxylated before conjugation, mainly with glucuronic acid. Hydroxylation occurred in the benzofuran ring and/or the ethyl side-chain. The principal urinary metabolite in humans was the conjugate(s) of the 1-hydroxylated ethyl side-chain derivative (mean 26% dose).
Related Compounds
Related Articles:
Interactions of urate transporter URAT1 in human kidney with uricosuric drugs.
2011-02-01
[Nephrology (Carlton.) 16(2) , 156-62, (2011)]
The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone.
2012-01-01
[PLoS ONE 7(4) , e34806, (2012)]
1983-01-01
[Arzneimittelforschung 33(2) , 211-4, (1983)]
1982-01-01
[Arzneimittelforschung 32(9) , 1114-20, (1982)]
[Drug modification of a risk factor of thrombosis in patients with varicosis].
1982-08-12
[Fortschr. Med. 100(30) , 1418-22, (1982)]